This year the conference brings its content, focused on the intersection of clinical research and patient care, from the real world to the virtual one.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
eClinical Solutions, a provider of clinical data service solutions, has seen an increase in interest in clinical data platform and other digital products.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
The survey, unveiled ahead of next week's CPhI Festival of Pharma, reveals perspectives, concerns and future plans of more than 500 industry executives.
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.
A recent study from the clinical research services firm indicates the pandemic continues to significantly impact clinical trial sites around the globe.
The US agency continues to issue advice for life-sciences professionals engaged in work related to the virus, and keep an eye out for fraudulent products.
The technology from Opyl uses artificial intelligence to anticipate a COVID-19 treatment, vaccine, diagnostic or device’s chances of success in a study.
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
